Brief: Kintor Pharmaceutical Says US FDA Greenlighted Phase III Clinical Trial Of Proxalutamide
18/05/2021 16:02
May 18 (Reuters) - Kintor Pharmaceutical Ltd 9939.HK :
* US FDA GREENLIGHTED PHASE III CLINICAL TRIAL OF
PROXALUTAMIDE
FOR TREATMENT OF HOSPITALISED COVID-19 PATIENTS
Source text https://www1.hkexnews.hk/listedco/listconews/sehk/2021/0518/2021051801150.pdf
Further company coverage: 9939.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Kintor Pharmaceutical
See all newsBrief: Kintor Pharmaceutical Receives Invention Patent Grant For KT-939 In China
Brief: Kintor Pharmaceutical Says Ming Ming Cheung Resigns As CFO
Brief: Kintor Pharmaceutical Says CEO Via Wholly Owned Co Increases Shareholding By 2.51 Million Shares
Brief: Kintor Pharmaceutical Says YTD 2026 Sales Revenue At RMB34 Million
Brief: Kintor Pharmaceutical Says Pharma's Kx-826 Phase Iii Trial In China Reaches Primary Endpoint